vida: extract claims from 2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data

- Source: inbox/queue/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/oregon-psilocybin-access-gap-is-demand-side-cost-failure-not-supply-side-capacity-constraint.md

@@ -11,9 +11,16 @@ sourced_from: health/2025-01-29-pmc-oregon-psilocybin-facilitator-workforce-surv
 scope: structural
 sourcer: Journal of Psychoactive Drugs
 challenges: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-expanding-access"]
-related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-expanding-access", "psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-expanding-access", "psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability", "psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component"]
 ---
 
 # Oregon's psilocybin access gap is a demand-side cost failure, not a supply-side capacity problem — facilitators have capacity for 60,000 clients/year but only 4,500/year are being served because session costs ($1,200-3,000) are uninsured and out-of-pocket
 
 Oregon licensed approximately 500 psilocybin facilitators by Q1 2026, each with capacity to serve ~10 clients/month (mean intended monthly clients from survey). This creates theoretical capacity of 60,000 clients/year. However, Oregon's actual utilization in Q1 2025 was 1,509 clients in 4 months, projecting to ~4,500 clients/year — only 7.5% of facilitator capacity. Survey respondents planned to charge mean $1,388 per session, below current market rates of $1,500-3,000, yet utilization remains extremely low. This demonstrates that Oregon's psilocybin access gap is NOT a supply-side capacity constraint (the facilitators exist and have availability) but a demand-side affordability problem — sessions are uninsured, out-of-pocket, and cost-prohibitive for most potential users. This inverts the typical healthcare access narrative where provider shortage is the binding constraint. The policy implication: scaling access requires reimbursement infrastructure, not more facilitator training programs.
+
+
+## Supporting Evidence
+
+**Source:** OPB / Oregon Health Authority SB 303 Data, Q1 2025
+
+Sheri Eckert Foundation waitlist data shows hundreds waiting for 100 subsidized slots at $670K total cost ($6,700/person). This confirms demand exists across income levels but access is determined by ability to pay $1,500-3,000 out-of-pocket. The 74% income premium ($153K client average vs. $88K state median) quantifies the cost-driven selection effect.

inbox/archive/health/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md

@@ -7,10 +7,13 @@ date: 2025-07-03
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-11
 priority: high
 tags: [psilocybin, Oregon, equity, access, income-disparity, SB303, demographic-data, mental-health-supply-gap]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content